Wu Wun-Chin, Wang Yu, Chai Chok-Yung
Department of Electrical Engineering of National Penghu University, Penghu.
Chin J Physiol. 2008 Jun 30;51(3):152-9.
The aim of this study was to investigate the effects of the cannabinoid receptor agonist, WIN55212-2, and the cannabinoid receptor antagonist, SR141716A, on dopamine (DA) release evoked by KC1 (120 mM) microinjected into the striatum. The cannabinoid agonist WIN55212-2 (1 and 5 mg/kg, i.p.) dose-dependently attenuated DA release in the striatum, whereas the cannabinoid receptor antagonist SR141716A (3 mg/kg, i.p.) produced the opposite effect. SR141716A (3 mg/kg, i.p.) blocked the effects on DA release by WIN55212-2 (5 mg/kg, i.p.). Vehicle alone did not change DA release. These results suggest that cannabinoids modulate DA release in the striatum.
本研究的目的是探究大麻素受体激动剂WIN55212-2和大麻素受体拮抗剂SR141716A对向纹状体内微量注射120 mM氯化钾（KC1）所诱发的多巴胺（DA）释放的影响。大麻素激动剂WIN55212-2（1和5毫克/千克，腹腔注射）剂量依赖性地减弱纹状体内的DA释放，而大麻素受体拮抗剂SR141716A（3毫克/千克，腹腔注射）则产生相反的效果。SR141716A（3毫克/千克，腹腔注射）阻断了WIN55212-2（5毫克/千克，腹腔注射）对DA释放的影响。单独使用溶剂不会改变DA释放。这些结果表明，大麻素可调节纹状体内的DA释放。
